PT - JOURNAL ARTICLE AU - T Bradbury AU - S Ananth AU - S Hussaini AU - A Mathioudakis AU - R Nguyen AU - C Jenkins TI - Exacerbation outcome definitions in clinical trials of COPD interventions: a systematic review AID - 10.1183/13993003.congress-2022.1239 DP - 2022 Sep 04 TA - European Respiratory Journal PG - 1239 VI - 60 IP - suppl 66 4099 - http://erj.ersjournals.com/content/60/suppl_66/1239.short 4100 - http://erj.ersjournals.com/content/60/suppl_66/1239.full SO - Eur Respir J2022 Sep 04; 60 AB - Introduction: In clinical trials of COPD interventions, the underlying definition of an “exacerbation” as a measured outcome remains inconsistent and unstandardised. This study reviews published clinical trials to describe how these medical events are defined as trial outcomes.Method: Journal articles describing the results of clinical trials with ≥100 enrolled participants published from 1995-2020 were identified from the Cochrane Central Register of Controlled Trials and reviewed for inclusion in the study.Results: A search of 7586 results provided 243 eligible publications describing the results of 254 trials. Exacerbation definitions (n=176) were classified by their constituent attributes: symptom (n=54), treatment (n=13), hybrids of the former two groups (n=109); and undefined (n=70). Heterogeneity was observed across all types of definition (Table 1). Exacerbation severity algorithms showed varying definitions for mild events. Moderate events (n=90) were consistently defined by systemic corticosteroid and/or antibiotic usage (n=71), and severe events (n=97) by hospital admission (n=96).Conclusion: Definitions of an “exacerbation” of COPD in clinical trials are heterogenous. This impacts how data are interpreted, compared and later implemented in clinical recommendations and practice. Further work is needed to reach consensus on how these consequential events should be defined and measured in clinical trials.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 1239.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).